Europe Molecular Diagnostics Market

Europe Molecular Diagnostics Market Size (2023 to 2028)

The European molecular diagnostics market is forecasted to grow at a CAGR of 8.45% between 2023 and 2028.

The rise in the large number of the senior population is driving the Europe Molecular Diagnostics Market. As aged people are apt to get a chronic illnesses, Europe witnessed a gradual increase in the prevalence of chronic diseases like diabetes, cancer, cardiovascular diseases, etc. In addition, the growing awareness and acceptance of personalized medicines among the people and the increasing prevalence of infectious diseases and various types of cancer increase awareness and acceptance of personalized medicines are boosting the Europe Molecular Diagnostics Market. Moreover, the advancements in molecular techniques have made diagnosis much cheaper and more accurate, propelling the Europe Molecular Diagnostics Market. Further, the rise in genetic diseases is pushing the market growth. For instance, according to global genes in 2015, more than 30 million people in Europe suffered from various rare genetic disorders. Further, the increase in demand for portable devices is fueling the market.

Due to poor reimbursement policies, the Europe molecular diagnostic market for group A streptococcus (GAS) nucleic acid (NA) tests is being obstructed. The differing criteria for nucleic acid tests in different European countries hinder the Europe Molecular Diagnostics Market during the forecast period. Moreover, the delays in the molecular diagnostic tests’ approvals paused the growth of the Europe Molecular Diagnostics Market. Furthermore, due to low expenditures on the healthcare sector, a lack of proper facilities in some European countries is further hindering the growth of the Europe Molecular Diagnostics Market. Additionally, the lack of well-skilled front-line workers and the lack of awareness among the people on early diagnosis in some parts of Europe limit market growth. 

COVID-19 Impact on Europe Molecular Diagnostics Market:

The European healthcare system was adversely impacted due to the Covid pandemic. Meanwhile, the European Molecular Diagnostics Market was positively impacted during the pandemic. The increase in respiratory diagnostic tests and the rise in demand for infectious disease tests, especially respiratory tests, are gradually increased during the pandemic. Moreover, due to the high COVID-19 impact in Italy and Spain, they have increased the clinical laboratories, which boosts the Europe Molecular Diagnostics Market.

This research report on the European molecular diagnostics market has been segmented & sub-segmented into the following categories.

By Products and Service:

• Reagents and kits

• Instruments

• Software and service

By Technology:

• Polymerase Chain Reaction (PCR)

• Isothermal Nucleic Acid Amplification Technology (INAAT)3.

• DNA Sequencing and NGS

• DNA Microarrays

• In Situ Hybridization

• Other Technologies

By End-User:

• Hospital and Academic Laboratories

• Reference Laboratories

• Other End-Users

By Country:

• UK

• France

• Spain

• Germany

• Italy

• Russia

• Sweden

• Denmark

• Switzerland

• Netherlands

• Turkey

• Czech Republic

• Rest of Europe

Geographically, Europe is expected to grow at the third-highest rate during the forecast period. The Europe Molecular Diagnostics Market size was valued at USD 1,750.0 million in 2015 and is expected to have attractive growth over the forecast period. The increase in the geriatric population and improving healthcare services quality are driving the Europe Molecular Diagnostics Market. Technological advancements like polymerase chain reaction (PCR) recognize the antimicrobial resistance genes and give public health information like strain characterization by genotyping that boosts the market. In addition, the rise in advancements in pharmacogenomics rise in the aging population associated with chronic diseases is promoting the market growth. For instance, in 2017, World Health Organisation (WHO) stated that the European population would increase to 910 million, and the majority of the elderly population would suffer from chronic diseases. Germany is the major contributor to the Europe Molecular Diagnostics Market during the forecast period. Technological advances in molecular diagnosis are driving the German market. Technological advancements like polymerase chain reaction (PCR) recognize the antimicrobial resistance genes and give public health information like strain characterization by genotyping.

KEY MARKET PLAYERS:

Companies such as Abbott Laboratories, Agilent Technologies, Becton, Dickinson And Company, Biomérieux SA, Danaher Corporation, Diasorin, Grifols, Hologic, Illumina, Qiagen, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific are currently playing a leading role in the European molecular diagnostics market.